# Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

> **NCT00378235** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **INSYS Therapeutics Inc**

## Conditions studied

- Recurrent Malignant Glioma

## Interventions

- **DRUG:** IL13-PE38QQR

## Key facts

- **NCT ID:** NCT00378235
- **Lead sponsor:** INSYS Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** There was a change of sponsor. The new sponsor company did not wish to conduct the study after all.
- **Last updated:** 2014-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00378235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00378235, "Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00378235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*